公开(公告)号：EP2271630A1

公开(公告)日：2011-01-12

申请号：EP09730392.9

申请日：2009-04-03

申请人： IRM LLC ,  Novartis AG

发明人： CHEN, Bei ,  JIANG, Tao ,  MARSILJE, Thomas, H. ,  MICHELLYS, Pierre-Yves ,  NGUYEN, Truc, Ngoc ,  PEI, Wei ,  WU, Baogen ,  GAO, Zhaobo ,  GE, Yonghui ,  HUANG, Chen ,  LI, Yuncheng ,  ZHU, Xuefeng

IPC分类号： C07D239/48 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61P35/00 ,  A61P37/00 ,  A61P31/00

CPC分类号： C07D239/48 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04

摘要： The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof.

摘要翻译： 本发明提供了新的嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶衍生物可用于治疗，改善或预防对抑制间变性淋巴瘤激酶（ALK）活性，c-ros致癌基因（ROS），胰岛素样生长因子（IGF-1R） ）和/或胰岛素受体（InsR）或其组合。

公开(公告)号：EP2091918A2

公开(公告)日：2009-08-26

申请号：EP07864693.2

申请日：2007-11-20

申请人： IRM LLC

发明人： MICHELLYS, Pierre-Yves ,  PEI, Wei ,  MARSILJE, Thomas H. ,  LU, Wenshuo ,  CHEN, Bei ,  UNO, Tetsuo ,  JIN, Yunho ,  JIANG, Tao

IPC分类号： C07D213/74 ,  C07D239/48 ,  C07D239/95 ,  C07D401/12

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/74 ,  C07D239/48 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D451/02 ,  C07D453/02 ,  C07D471/04 ,  C07D473/16 ,  C07D487/04 ,  C07D487/08

摘要： The invention provides novel pyrimidine and pyridine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 ZAP-70), insulin-like growth factor (IGF- 1R), or a combination thereof.

摘要翻译： 本发明提供了式（I）的新的嘧啶和吡啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶和吡啶衍生物可用于治疗，改善或预防对抑制间变性淋巴瘤激酶（ALK）活性，粘着斑激酶（FAK），ζ链相关蛋白激酶70 ZAP-70），胰岛素样生长因子（IGF-1R）或其组合。

公开(公告)号：EP1778242A2

公开(公告)日：2007-05-02

申请号：EP05776623.0

申请日：2005-07-28

申请人： IRM LLC

发明人： MICHELLYS, Pierre-Yves ,  PETRASSI, H. Michael ,  RICHMOND, Wendy ,  PEI, Wei

IPC分类号： A61K31/538 ,  C07D265/36

CPC分类号： C07D263/58 ,  C07D265/36 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear receptors.

公开(公告)号：EP2091918B1

公开(公告)日：2014-08-27

申请号：EP07864693.2

申请日：2007-11-20

申请人： IRM LLC

发明人： MICHELLYS, Pierre-Yves ,  PEI, Wei ,  MARSILJE, Thomas H. ,  CHEN, Bei ,  UNO, Tetsuo

IPC分类号： C07D213/74 ,  C07D239/48 ,  C07D239/95 ,  C07D401/12

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/74 ,  C07D239/48 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D451/02 ,  C07D453/02 ,  C07D471/04 ,  C07D473/16 ,  C07D487/04 ,  C07D487/08

公开(公告)号：EP2271645A1

公开(公告)日：2011-01-12

申请号：EP09731237.5

申请日：2009-04-03

申请人： IRM LLC

发明人： JIANG, Tao ,  MICHELLYS, Pierre-Yves ,  NGUYEN, Truc, Ngoc ,  PEI, Wei ,  WU, Baogen ,  ZHU, Xuefeng

IPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/53 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D471/04

摘要： The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.

公开(公告)号：EP1865775A1

公开(公告)日：2007-12-19

申请号：EP06749458.3

申请日：2006-04-06

申请人： IRM, LLC

发明人： MICHELLYS, Pierre-Yves ,  WEN, Ke ,  PETRASSI, Michael, H. ,  PEI, Wei

IPC分类号： A01N43/58 ,  A01N43/60 ,  A01N43/54 ,  A01N43/42 ,  A61K31/50 ,  A61K31/495 ,  A61K31/517 ,  A61K31/47 ,  C07D237/30 ,  C07D239/72 ,  C07D401/00 ,  C07D403/00 ,  C07D413/00 ,  C07D417/00 ,  C07D419/00 ,  C07D217/00 ,  C07D217/22

CPC分类号： C07D213/50 ,  C07D401/06 ,  C07D417/12 ,  C07D417/14

摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent diseases or conditions associated with the activity of steroid hormone nuclear receptors.

公开(公告)号：EP1850844A2

公开(公告)日：2007-11-07

申请号：EP06758162.9

申请日：2006-02-16

申请人： IRM, LLC

发明人： MICHELLYS, Pierre-Yves ,  MAK, Chi Ching ,  PEI, Wei

IPC分类号： A61K31/397

CPC分类号： C07D498/10 ,  C07D263/52

摘要： Described herein are compounds that have a spiro structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent diseases or conditions associated with the activity of steroid hormone nuclear receptors.

公开(公告)号：EP1828135A2

公开(公告)日：2007-09-05

申请号：EP05849955.9

申请日：2005-12-13

申请人： IRM, LLC

发明人： MICHELLYS, Pierre-Yves ,  PEI, Wei ,  WITYAK, John

IPC分类号： C07D213/84 ,  C07D213/85 ,  A61K31/44

CPC分类号： C07D211/90 ,  C07D215/48 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04

摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear receptors.

公开(公告)号：EP2271630B1

公开(公告)日：2016-03-23

申请号：EP09730392.9

申请日：2009-04-03

申请人： Novartis AG

发明人： CHEN, Bei ,  JIANG, Tao ,  MARSILJE, Thomas, H. ,  MICHELLYS, Pierre-Yves ,  NGUYEN, Truc, Ngoc ,  PEI, Wei ,  WU, Baogen ,  GAO, Zhaobo ,  GE, Yonghui ,  HUANG, Chen ,  LI, Yuncheng ,  ZHU, Xuefeng

IPC分类号： C07D239/48 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61P35/00 ,  A61P37/00 ,  A61P31/00

CPC分类号： C07D239/48 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04

公开(公告)号：EP4059934A1

公开(公告)日：2022-09-21

申请号：EP21208454.5

申请日：2017-09-06

申请人： Novartis AG

发明人： ALPER, Phillip ,  DEANE, Jonathan ,  JIANG, Songchun ,  JIANG, Tao ,  KNOEPFEL, Thomas ,  MICHELLYS, Pierre-Yves ,  MUTNICK, Daniel ,  PEI, Wei ,  SYKA, Peter ,  ZHANG, Guobao ,  ZHANG, Yi

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P37/00

摘要： The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.